Loading stock data…
DCTH
$10.80+0.42 (+4.05%)
Market ClosedLast close May 1
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Delcath Systems, Inc. in the Healthcare sector is trading at $10.80. The stock is currently 41% below its 52-week high of $18.23, remaining 6.0% above its 200-day moving average. Technical signals show neutral RSI of 55 and bearish MACD signal, explaining why DCTH maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 55) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$10.80
Potential Downside
88.5%
Whystock Fair Value$1.24
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delive...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$388.81M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
159.86
Beta
Defensive asset. Lower volatility than the S&P 500.
0.43
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
2.01%
Volume
Today's trading volume
169,780
Recent News
How The Delcath Systems (DCTH) Story Is Shifting With Hepzato Milestones And 2026 Guidance
Analysts now reference a revised US$27 price target for Delcath Systems, while the model based Fair Value remains steady at US$21.33. Bullish voices see that US$27 level as still offering upside relative to current trading, backed by FY26 sales guidance of at least US$100m and increased spending on HEPZATO related R&D and commercial expansion, while more cautious views focus on the gap to the US$111m consensus and higher operating costs. Read on to see how to track these competing narratives...
Implied Volatility Surging for Delcath Systems Stock Options
Investors need to pay close attention to DCTH stock based on the movements in the options market lately.
Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology
Delcath Systems (DCTH) announced the publication of the full results from the investigator-initiated CHOPIN randomized Phase 2 clinical trial, led by Principal Investigator Professor Ellen Kapiteijn from Leiden University Medical Center’s Department of Medical Oncology. The publication, titled “Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma: a single-centre, open-label, randomised, phase 2 trial” is published in The Lancet Oncology and present
Delcath Systems Inc (DCTH) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic ...
Delcath Systems Inc (DCTH) reports record annual revenue of $85.2 million, outlines 2026 growth strategies, and addresses challenges in R&D expenses and seasonal impacts.
Delcath Systems Q4 Earnings Call Highlights
Delcath Systems (NASDAQ:DCTH) reported record results for 2025 and outlined a commercial and clinical roadmap that management believes can support continued growth, emphasizing expanding treatment-center capacity, increasing new patient starts, and strengthening referral networks. On the company’s f